CYTK on Nasdaq

Cytokinetics

California-based biopharmaceutical company

Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function.3 From Wikipedia, CC BY-SA 4.0

Price unavailable

Last updated Oct 19, 2026.

Overview

1997Founded1

Compare with Amylyx Pharmaceuticals, Standard BioTools Inc. or Silverback Therapeutics, or pick any stock.

  • TickerCYTK on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersSouth San Francisco1
  • Websitecytokinetics.com
  • Legal formDelaware corporation1
  • Business address350 Oyster Point Boulevard, ., South San Francisco, Ca 940805
  • Filer categoryLarge accelerated filer5
  • LEI549300BE5DY1HW7IHA644
  • StatusActive4
  • LEI statusLapsed (not renewed)4
  • Registered address251 LITTLE FALLS DRIVE, 19808 Wilmington, United States4
  • Registered withDivision of Corporations, Department of State, 27816264

See how the biggest companies compare on our leaderboards

Cytokinetics Headquarters
Photo: Coolcaesar, CC BY-SA 4.0, via Wikimedia Commons7

Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-695.4%Operating margin8
-891.6%Net margin8
376.6%Revenue growth, 20258
-$534.8MFree cash flow8

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

License and Milestone Revenues brought in 90% of the revenue Cytokinetics broke down this way in fiscal 2025.

  1. License and Milestone Revenues$79.4M890%up 429% from 2024
  2. Collaboration Revenues$8.7M810%up 150% from 2024
Products and services by year
Products and services2021202320242025
License and Milestone Revenues$54.9M$3.5M$15.0M$79.4M
Collaboration Revenues$4.0M$3.5M$8.7M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development90¢$416.0M
  • Interest10¢$45.6M

Out of $88.0M in revenue.8 The company lost money this year.

Financial statements

Revenue91011128$88.0M in 2025+228% since 2019
0$25.0M$50.0M$75.0M$100.0M2019: $26.9M$26.9M20192020: $55.8M$55.8M2020+108%2021: $70.4M$70.4M2021+26%2022: $94.6M$94.6M2022+34%2023: $7.5M$7.5M2023−92%2024: $18.5M$18.5M2024+145%2025: $88.0M$88.0M2025+377%
Operating income91011128-$612.3M in 2025+519% since 2019
-$800.0M-$600.0M-$400.0M-$200.0M02019: -$98.9M-$98.9M20192020: -$93.9M-$93.9M2020−5%2021: -$186.3M-$186.3M2021+98%2022: -$324.2M-$324.2M2022+74%2023: -$496.2M-$496.2M2023+53%2024: -$536.2M-$536.2M2024+8%2025: -$612.3M-$612.3M2025+14%
Net income91011128-$785.0M in 2025+545% since 2019
-$800.0M-$600.0M-$400.0M-$200.0M02019: -$121.7M-$121.7M20192020: -$127.3M-$127.3M2020+5%2021: -$215.3M-$215.3M2021+69%2022: -$389.0M-$389.0M2022+81%2023: -$526.2M-$526.2M2023+35%2024: -$589.5M-$589.5M2024+12%2025: -$785.0M-$785.0M2025+33%

Every line of the income statement as filed: the last 3 fiscal years, latest first.8

Period ending2025-12-312024-12-312023-12-31
Total revenues$88.0M$18.5M$7.5M
Research and development$416.0M$339.4M$330.1M
General and administrative$284.3M$215.3M$173.6M
Total operating expenses$700.3M$554.7M$503.7M
Operating loss-$612.3M-$536.2M-$496.2M
Interest expense-$45.6M-$37.7M-$28.3M
Non-cash interest expense on liabilities related to revenue participation right purchase agreements-$58.3M-$48.8M-$29.4M
Interest and other income, net$48.4M$51.5M$27.6M
Change in fair value of derivative liabilities$4.2M$1.3M$0
Change in fair value of liabilities related to RPI Transactions-$200.0K-$19.6M$0
Debt conversion expense-$121.2M$0$0
Net loss-$785.0M-$589.5M-$526.2M
Net loss per share - basic-$6.54-$5.26-$5.45
Net loss per share - diluted-$6.54-$5.26-$5.45
Weighted-average number of shares used in computing net loss per share - basic120.1K shares112.0K shares96.5K shares
Weighted-average number of shares used in computing net loss per share - diluted120.1K shares112.0K shares96.5K shares
Unrealized (loss) gain on available-for-sale securities, net-$990.0K$2.2M$3.6M
Foreign currency translation adjustments-$778.0K$255.0K-$20.0K
Comprehensive loss-$786.7M-$587.1M-$522.7M

Compare Cytokinetics with another company

The story

Cytokinetics was founded in 1997 by James Spudich, Ronald Vale, James Sabry and Lawrence S.B. Goldstein, four scientists at Stanford, UCSD, and UCSF. Operations began in 1998.

Initially, Cytokinetics focused on the possible pharmacological targets and areas of application of drugs based on cytoskeletal proteins. Eventually, the company narrowed its focus to the mechanics of muscle biology. Cytokinetics develops muscle activators and muscle inhibitors to improve muscle function in patients with cardiovascular and neuromuscular diseases.

In 2004 the company completed its initial public offering (IPO).

In January 2007, Cytokinetics named Robert I. Blum as president and CEO. Prior to this, Blum has been involved in the company since its founding, with roles in business development, corporate development and R&D.

In 2013, Cytokinetics finalized a licensing and discovery deal with Astellas to research treatment for muscle weakness and fatigue.

In July 2020, Ji Xing Pharmaceuticals signed a financing deal with Cytokinetics, which included the rights to commercialize the drug designed to treat hypertrophic cardiomyopathies, aficamten, in China and certain neighboring regions.

From Wikipedia’s article on Cytokinetics, shared under CC BY-SA 4.0.6

Leadership

Who has led Cytokinetics, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. James H. Sabry2006–2007
  2. Robert I. Blum2007–now

Chair

  1. James H. Sabry2007–2009

President

  1. James H. Sabry2006
  2. Robert I. Blum2006–now

Chief financial officer

  1. Sharon Surrey Barbari2006–2017
  2. Ching Jaw2017–2023
200020052010201520202025
Board members and other officers (39)

Products and brands

Omecamtiv mecarbil is a cardiac muscle activator for the potential treatment of heart failure. In May 2020, omecamtiv mecarbil was granted fast track designation by the FDA for the treatment of chronic HF with reduced ejection fraction. Amgen purchased an option on omecamtiv mecarbil in 2006, and the two companies extended their partnership several times. In June 2013, Cytokinetics and Amgen expanded their licensing deal for omecamtiv mecarbil to include Japan. In November 2020 Amgen elected to terminate the collaboration, effective May 20, 2021, and Cytokinetics regained worldwide rights to develop and commercialize omecamtiv mecarbil.

Reldesemtiv (previously known as CK-2127107) is a next-generation fast skeletal muscle troponin activator (FSTA) that has undergone clinical trials for ALS.

Aficamten (previously known as CK-3773274) is an oral, small-molecule myosin inhibitor, to treat hypertrophic cardiomyopathy (HCM).

From Wikipedia’s article on Cytokinetics, shared under CC BY-SA 4.0.6

Timeline

  1. Mar 16, 2007New chief executive Robert I. Blum becomes CEO16
  2. Feb 9, 2006New chief executive James H. Sabry becomes CEO17
  3. Apr 29, 2004Went public Listed on NASDAQ1
  4. 1997Founded Founded1

Filings

880 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 113 major events, 544 insider forms, 38 large holders, 165 other. The latest 20:

  1. Oct 13, 2026144 EDGAR
  2. Oct 13, 20264 PRIMARY DOCUMENT EDGAR
  3. Oct 6, 20264 PRIMARY DOCUMENT EDGAR
  4. Sep 28, 20264 PRIMARY DOCUMENT EDGAR
  5. Sep 22, 20264 PRIMARY DOCUMENT EDGAR
  6. Sep 15, 2026144 EDGAR
  7. Sep 15, 20264 PRIMARY DOCUMENT EDGAR
  8. Sep 15, 20264 PRIMARY DOCUMENT EDGAR
  9. Sep 11, 2026144 EDGAR
  10. Sep 11, 20264 PRIMARY DOCUMENT EDGAR
  11. Sep 8, 20264 PRIMARY DOCUMENT EDGAR
  12. Sep 1, 2026144 EDGAR
  13. Sep 1, 20264 PRIMARY DOCUMENT EDGAR
  14. Aug 31, 20264 PRIMARY DOCUMENT EDGAR
  15. Aug 31, 20264 PRIMARY DOCUMENT EDGAR
  16. Aug 28, 20268-K EDGAR
  17. Aug 18, 20264 PRIMARY DOCUMENT EDGAR
  18. Aug 13, 20268-K EDGAR
  19. Aug 13, 2026SCHEDULE 13G/A EDGAR
  20. Aug 10, 20264 PRIMARY DOCUMENT EDGAR

The 880 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

298 open-market trades by officers, directors and large owners since October 2021: 0 buys and 298 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 28, 2026Blum Robert IPresident & CEOSale7,500$65.46$490.9KForm 4
Sep 22, 2026Malik Fady IbrahamEVP Research & DevelopmentSale3,500$68.29$239.0KForm 4
Sep 15, 2026Landry Robert EDirectorSale1,000$72.13$72.1KForm 4
Sep 15, 2026Blum Robert IPresident & CEOSale97,926$69.33$6.8MForm 4
Sep 14, 2026Blum Robert IPresident & CEOSale7,500$73.44$550.8KForm 4
Sep 11, 2026Landry Robert EDirectorSale1,000$74.66$74.7KForm 4
Sep 8, 2026Malik Fady IbrahamEVP Research & DevelopmentSale3,500$75.46$264.1KForm 4
Sep 1, 2026PARSHALL B LYNNEDirectorSale5,000$71.48$357.4KForm 4
Aug 31, 2026Callos AndrewEVP, Chief Commercial OfficerSale10,000$70.24$702.4KForm 4
Aug 31, 2026Blum Robert IPresident & CEOSale7,500$70.24$526.8KForm 4
Aug 18, 2026Malik Fady IbrahamEVP Research & DevelopmentSale3,500$75.82$265.4KForm 4
Aug 10, 2026Blum Robert IPresident & CEOSale7,500$76.76$575.7KForm 4
Jul 30, 2026Callos AndrewEVP, Chief Commercial OfficerSale14,000$79.88$1.1MForm 4
Jul 27, 2026Blum Robert IPresident & CEOSale7,500$80.87$606.5KForm 4
Jul 21, 2026Malik Fady IbrahamEVP Research & DevelopmentSale3,500$80.59$282.1KForm 4
Jul 13, 2026Blum Robert IPresident & CEOSale7,500$82.02$615.1KForm 4
Jul 7, 2026Malik Fady IbrahamEVP Research & DevelopmentSale3,500$86.62$303.2KForm 4
Jul 1, 2026Blum Robert IPresident & CEOSale7,500$84.92$636.9KForm 4
Jul 1, 2026Callos AndrewEVP, Chief Commercial OfficerSale15,000$85.80$1.3MForm 4
Jul 1, 2026Lee SungEVP, Chief Financial OfficerSale1,112$87.79$97.6KForm 4

All 298 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
BlackRock, Inc.20,094,362$1.7B0.0%+3,546,351
Wellington Management Group Llp6,931,770$590.5M0.1%−1,077,719
Vanguard Portfolio Management LLC6,711,799$571.8M0.0%+868,017
State Street Corp6,494,233$553.2M0.0%+749,040
Vanguard Capital Management LLC6,117,515$521.2M0.0%+628,881
Fmr LLC5,031,782$428.7M0.0%−5,691,358
Avoro Capital Advisors LLC4,999,999$425.9M3.8%+1,666,666
Bank Of America Corp /de/4,635,709$394.9M0.0%+1,510,273
Geode Capital Management, LLC3,712,501$316.3M0.0%+497,086
Rtw Investments, LP2,862,003$243.8M2.1%+140,845
Polar Capital Holdings Plc2,253,649$192.0M0.5%+592,401
Goldman Sachs Group Inc1,761,588$150.1M0.0%−444,170
Capital Research Global Investors1,686,625$143.7M0.0%+915,626
Northern Trust Corp1,647,345$140.3M0.0%+205,711
Jpmorgan Chase & Co1,588,895$139.2M0.0%+685,090
William Blair Investment Management, LLC1,603,442$136.6M0.4%+515,851
Integral Health Asset Management, LLC1,600,000$136.3M5.6%No change
Point72 Asset Management, L.P.1,587,712$135.3M0.2%+961,610
Charles Schwab Investment Management Inc1,565,781$133.4M0.0%+168,736
Susquehanna International Group, Llp1,549,458$132.0M0.1%+650,507
Morgan Stanley1,510,318$128.7M0.0%+5,243
Principal Financial Group Inc1,311,664$111.7M0.1%+218,179
Capital International Investors1,305,848$111.2M0.0%−32,955
Invesco Ltd.1,235,323$105.2M0.0%+750,343
Armistice Capital, LLC1,201,342$102.3M2.8%+436,804

13F reports cover disclosed long positions in U.S. stocks only.

Members of Congress who traded it

5 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

DateMemberTradeAmountVs S&P sinceFiling
Sep 29, 2026Gilbert Ray Cisneros, Jr.Democratic, HouseBuy$1,001 - $15,000−6.6%Report
Jun 30, 2026Gilbert Ray Cisneros, Jr.Democratic, HouseBuy$1,001 - $15,000−30.6%Report
Oct 9, 2025Gilbert Ray Cisneros, Jr.Democratic, HouseBuy$1,001 - $15,000−12.3%Report
Jun 17, 2025Lisa C. McClainRepublican, HouseSale$1,001 - $15,000−61.2%Report
Jun 11, 2025Lisa C. McClainRepublican, HouseBuy$1,001 - $15,000+58.8%Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67